Logimed Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 12-12-2024
- Paid Up Capital ₹ 0.10 M
as on 12-12-2024
- Company Age 9 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 0.70 M
as on 12-12-2024
- Revenue 10.82%
(FY 2022)
- Profit 13.78%
(FY 2022)
- Ebitda 5.42%
(FY 2022)
- Net Worth 26.88%
(FY 2022)
- Total Assets 8.14%
(FY 2022)
About Logimed Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹0.70 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Vinay Chadha and Ashwani Tejpal serve as directors at the Company.
- CIN/LLPIN
U24232CH2015PTC035450
- Company No.
035450
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Mar 2015
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Logimed Pharma Private Limited offer?
Logimed Pharma Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antifungal Cream, Ointment & Powder, Pain Relief Drugs & Pharmaceuticals, Diclofenac, Muscle Relaxant, Aceclofenac, Common Disease Medicines, Pharmaceutical Medicine, Digestive System Drugs & Medicines, Antacid Drugs.
Who are the key members and board of directors at Logimed Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinay Chadha  | Director | 11-Mar-2015 | Current |
| Ashwani Tejpal | Director | 12-Apr-2017 | Current |
Financial Performance of Logimed Pharma.
Logimed Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 10.82% increase. The company also saw a substantial improvement in profitability, with a 13.78% increase in profit. The company's net worth Soared by an impressive increase of 26.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Logimed Pharma?
In 2022, Logimed Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 26 Dec 2017 | ₹0.70 M | Satisfied |
How Many Employees Work at Logimed Pharma?
Unlock and access historical data on people associated with Logimed Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Logimed Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Logimed Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
